AstraZeneca (AZN) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for AstraZeneca (LON: AZN):

  • 10/12/2018 – AstraZeneca had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc. They now have a GBX 5,800 ($75.79) price target on the stock.
  • 10/10/2018 – AstraZeneca had its “sell” rating reaffirmed by analysts at Goldman Sachs Group Inc.
  • 10/9/2018 – AstraZeneca had its “overweight” rating reaffirmed by analysts at Barclays PLC.
  • 10/8/2018 – AstraZeneca had its price target raised by analysts at Deutsche Bank AG from GBX 6,000 ($78.40) to GBX 6,400 ($83.63). They now have a “buy” rating on the stock.
  • 9/26/2018 – AstraZeneca was given a new GBX 4,080 ($53.31) price target on by analysts at Goldman Sachs Group Inc. They now have a “sell” rating on the stock.
  • 9/25/2018 – AstraZeneca had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a GBX 5,900 ($77.09) price target on the stock.
  • 9/25/2018 – AstraZeneca was given a new GBX 6,500 ($84.93) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 9/25/2018 – AstraZeneca had its “buy” rating reaffirmed by analysts at Citigroup Inc. They now have a GBX 6,200 ($81.01) price target on the stock.
  • 9/25/2018 – AstraZeneca had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 6,000 ($78.40) price target on the stock.
  • 9/24/2018 – AstraZeneca had its “overweight” rating reaffirmed by analysts at Barclays PLC.
  • 9/24/2018 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital.
  • 9/24/2018 – AstraZeneca had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 9/20/2018 – AstraZeneca was given a new GBX 4,080 ($53.31) price target on by analysts at Goldman Sachs Group Inc. They now have a “sell” rating on the stock.
  • 9/18/2018 – AstraZeneca was given a new GBX 6,500 ($84.93) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 9/17/2018 – AstraZeneca had its “overweight” rating reaffirmed by analysts at Barclays PLC.
  • 9/14/2018 – AstraZeneca had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 9/11/2018 – AstraZeneca was given a new GBX 6,500 ($84.93) price target on by analysts at BNP Paribas. They now have a “buy” rating on the stock.
  • 9/7/2018 – AstraZeneca was downgraded by analysts at Jefferies Financial Group Inc to a “hold” rating. They now have a GBX 5,975 ($78.07) price target on the stock, down previously from GBX 6,200 ($81.01).
  • 9/7/2018 – AstraZeneca had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 9/7/2018 – AstraZeneca had its price target raised by analysts at Kepler Capital Markets from GBX 5,630 ($73.57) to GBX 6,100 ($79.71). They now have a “buy” rating on the stock.
  • 8/31/2018 – AstraZeneca was given a new GBX 4,080 ($53.31) price target on by analysts at Goldman Sachs Group Inc. They now have a “sell” rating on the stock.
  • 8/31/2018 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital.
  • 8/30/2018 – AstraZeneca had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/30/2018 – AstraZeneca was given a new GBX 6,350 ($82.97) price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 8/23/2018 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital.
  • 8/21/2018 – AstraZeneca had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a GBX 6,500 ($84.93) price target on the stock.
  • 8/20/2018 – AstraZeneca had its “top pick” rating reaffirmed by analysts at Barclays PLC.
  • 8/16/2018 – AstraZeneca was given a new GBX 6,200 ($81.01) price target on by analysts at Jefferies Financial Group Inc. They now have a “neutral” rating on the stock.
  • 8/15/2018 – AstraZeneca was given a new GBX 4,840 ($63.24) price target on by analysts at HSBC Holdings plc. They now have a “sell” rating on the stock.
  • 8/15/2018 – AstraZeneca had its “hold” rating reaffirmed by analysts at Shore Capital.

Shares of LON:AZN traded down GBX 70 ($0.91) during midday trading on Friday, hitting GBX 5,546 ($72.47). The company had a trading volume of 1,864,160 shares, compared to its average volume of 2,310,000. AstraZeneca plc has a twelve month low of GBX 4,260 ($55.66) and a twelve month high of GBX 5,520 ($72.13).

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: NASDAQ

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply